Alex DeWinter (GE Ventures) #NGDx18 Everything but drugs and implants. Clinical data analytics. For Dx: health economics looked at 1st.
12:22pm August 23rd 2018 via Twitter Web Client
Merkeley #NGDx18 They ask 'why has the market failed' and look for unique ways to partner, remove barriers etc.
12:18pm August 23rd 2018 via Twitter Web Client
Merkeley #NGDx18 Also dual-utility: sepsis affects 2M /year. Constantly look for opps to invest in. 12y: 38 FDA-app… https://t.co/6AoCrEvJu4
12:17pm August 23rd 2018 via Twitter Web Client
Merkeley #NGDx18 $1.5B budget; Congress recognizes that no one would develop products for an emergent threat (i.e. Anthrax)
12:16pm August 23rd 2018 via Twitter Web Client
Tyler Merkeley (BARDA) #NGDx18 $22M awarded for home flu tests. Teamed up with J&J for respiratory devices.
12:15pm August 23rd 2018 via Twitter Web Client
Haim #NGDx18 Majority emphasis on diagnostics side; October cycle; offer a lot of training opportunities as well
12:14pm August 23rd 2018 via Twitter Web Client
Haim #NGDx18 Want to talk, happy to engage pre-application; https://t.co/bP2vqz9FAd In Dx: conscious of commercial hurdles.
12:12pm August 23rd 2018 via Twitter Web Client
Haim #NGDx18 Can be much larger in later stages (up to $10M total); active in Cancer Moonshot, Opioid alternatives
12:11pm August 23rd 2018 via Twitter Web Client
Todd Haim (NCI SBIR) #NGDx18 Want to bring co's to next level of valuation, now more flexible. $300K or more, pre-clinical Stg I
12:10pm August 23rd 2018 via Twitter Web Client
Meuleman #NGDx18 $230M fund, lack of VCs who understood what it took to bring genomic tests to market. Also tools, dx not genomics-spec
12:09pm August 23rd 2018 via Twitter Web Client
Quinn #NGDx18 Investor in diagnostics: they face risk, skepticism, concerns. Panel: Wouter Meuleman (Ilumina Ventur… https://t.co/WENIxkFKFF
12:07pm August 23rd 2018 via Twitter Web Client
Next panel up at #NGDx18 Changing approaches to sustainable funding in diagnostics Moderator: Bruce Quinn (Bruce Quinn Assoc)
12:04pm August 23rd 2018 via Twitter Web Client
Tsongalis #NGDx18 Have been asking this question for 20y: how can the molecular lab add value to the pathologist?
11:59am August 23rd 2018 via Twitter Web Client
Q: Physicians' exposure vs this audience's exposure to NGS? #NGDx18 Icenhour: They train physicians 'every day'.
11:58am August 23rd 2018 via Twitter Web Client
Tsongalis #NGDx18 The consumer will have a lot more influence in the future!
11:57am August 23rd 2018 via Twitter Web Client
Scholz #NGDx18 Which of these data points actually help pts that we deal with? Tsongalis: Has two early-20's children, 'health-crazy'
11:56am August 23rd 2018 via Twitter Web Client
Icenhour #NGDx18 We now have power to discover, and thus go back to the broad look. Scholz: 'When information increases wisdom declines'
11:55am August 23rd 2018 via Twitter Web Client
Icenhour #NGDx18 Microbiome - 6 lbs/person of microbes, how does it affect behavior? Autism-like syndrome - could it be fungal inf? (!)
11:54am August 23rd 2018 via Twitter Web Client
Icenhour #NGDx18 Push for POCT - but we are going all the way back, to get a broad look. 'Just because you can doesn't mean you should'
11:53am August 23rd 2018 via Twitter Web Client
Icenhour #NGDx18 Predicts at least 1/2 'autoimmune' disorders are actually infections or microbiome-related (!)
Scholz #NGDx18 One option: collection of blood spots over time? Then test when longitudinal data is needed. A retrospective study
11:52am August 23rd 2018 via Twitter Web Client
Scholz #NGDx18 Regular monitoring of tests: cost is still a barrier. Collecting info even though it isn't needed. But needed when sick?
11:49am August 23rd 2018 via Twitter Web Client
Nagarajan #NGDx18 Interaction between pt, physician, got to be able to integrate data longitudinally.
11:48am August 23rd 2018 via Twitter Web Client
Nagarajan #NGDx18 Technology and data: all pieces in place (security-wise), amount of data is large but pieces in place...
11:47am August 23rd 2018 via Twitter Web Client
Nagarajan #NGDx18 Is it cost-effective, easy? Tsongalis: grew up with the Jetsons. Wearables too far-fetched?
Nagarajan #NGDx18 It's complexity, scale and automation; a defined, cheap device; specific vars or broad assay; run at POC. 'a possibility'
11:45am August 23rd 2018 via Twitter Web Client
Tsongalis #NGDx18 Asks how many think liquid biopsy is disruptive? (More hands) One day: handheld device to detect?… https://t.co/m9Su855FnC
11:43am August 23rd 2018 via Twitter Web Client
Scholz #NGDx18 The big change in ID: an immunoassay analyzer built for $3 and a $0.40 disposable, with 50 different strips.
11:41am August 23rd 2018 via Twitter Web Client
Scholz #NGDx18 For ID: 'moving from steel to plastic': production equipment dictates pricing (central lab model); n… https://t.co/jXZgF5HfFJ
11:40am August 23rd 2018 via Twitter Web Client
Scholz #NGDx18 Make panels for pathologists can do most of the work - if the cost and ease of use concerns are addressed.
11:39am August 23rd 2018 via Twitter Web Client
Scholz #NGDx18 Integration of pathologists to the geneticists; talks about simplicity of @pillar_bio - with someone… https://t.co/4jDuIIxLta
11:38am August 23rd 2018 via Twitter Web Client
Scholz #NGDx18 New technology like NGS - potentially disruptive when implemented. Pathologists who will talk with treating physicians
11:37am August 23rd 2018 via Twitter Web Client
Scholz #NGDx18 Decentralized is impt for quick decisions, and cost structure. For Cancer: will have limited/no benefit.
11:36am August 23rd 2018 via Twitter Web Client
Nagarajan #NGDx18 Also a 'gateway service' - outsourced sequencing, Getting a workforce trained in genomics impt.
11:35am August 23rd 2018 via Twitter Web Client
Nagarajan #NGDx18 A SaaS business model, a seamless workflow. Assay validation service to help their customers get going.
11:29am August 23rd 2018 via Twitter Web Client
Rakesh Nagarajan (PierianDx) #NGDx18 WashU clinical NGS with inh and cancer, validated clinical testing; spun out in '14
11:28am August 23rd 2018 via Twitter Web Client
Icenhour #NGDx18 CLIA-cert - for them is so different. They are getting reimbursed "it's hard, one pt was sick for… https://t.co/u55fDQFEqD
11:27am August 23rd 2018 via Twitter Web Client
Icenhour #NGDx18 Helped 800 people so far 'getting help they could not get anywhere'. Told it's impossible for FDA… https://t.co/pBjkiP6QXN
11:25am August 23rd 2018 via Twitter Web Client
Crystal Icenhour (Aperiomics) #NGDx18 They want to 'change everything' about both ID and autoimmune conditions.
11:24am August 23rd 2018 via Twitter Web Client
Scholtz: #NGDx18 With gene sequencing, the issue is at the level of the physician, 'how do I use this info?' Across… https://t.co/xQ1bdb5OvD
11:23am August 23rd 2018 via Twitter Web Client
Scholtz (Pillar Biosciences) #NGDx18 Diagnostics for 25-30y. If it's valuable and does it well, the FDA is not a problem.
11:22am August 23rd 2018 via Twitter Web Client
Tsongalis #NGDx18 Test utilization and regulation? When it happens 'at home'? The 'what ifs': it's going to happen; how to implement?
11:21am August 23rd 2018 via Twitter Web Client
Tsongalis #NGDx18 Into remarks to 'Disruptive technologies in lab medicine'. Wearables. Concepts of wellness. Microfluidics explosion.
11:20am August 23rd 2018 via Twitter Web Client
@Pillar_Bio own Manfred Scholz on a #NGDx18 disruptive technologies panel with Greg Tsongalis of @AMPath and… https://t.co/M0cQcE7bIa
11:18am August 23rd 2018 via Twitter for iPhone
Keyes #NGDx18 '16 PLoS One https://t.co/KT1KmEO5uK describing their small RNA adapters
9:43am August 23rd 2018 via Twitter Web Client
Keyes #NGDx18 Developed sterically blocked adapterswith a modified base, after screening some 250 candidates.
9:42am August 23rd 2018 via Twitter Web Client
Keyes #NGDx18 Electro-osmotic flow down a capillary, '14 ref https://t.co/riKUhjsxWa Nucleii can be separated from cytoplasm
9:37am August 23rd 2018 via Twitter Web Client
Keyes #NGDx18 Isotachophoresis, a discontinuous buffer with leading/trailing electrolytes. Sample as intermed ionic mobility
9:36am August 23rd 2018 via Twitter Web Client
Keys #NGDx18 Lays out the limitations of bulk methods. For total RNA run out on a Bioanalyzer: miRNA as a fraction of total RNA is small
9:29am August 23rd 2018 via Twitter Web Client
Dick Keys (Trilink) #NGDx18 Single-cell small RNA-seq by microfluidic chip isotachophoresis with sRNA library prep using modified adapters
9:24am August 23rd 2018 via Twitter Web Client
